tetano
Editor, Senior Moderator
Br J Haematol
. 2022 Nov 28.
doi: 10.1111/bjh.18578. Online ahead of print.
Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia
Akio Mori[SUP] 1 [/SUP], Masahiro Onozawa[SUP] 2 [/SUP], Mirei Kobayashi[SUP] 1 [/SUP], Shihori Tsukamoto[SUP] 1 [/SUP], Hajime Senjo[SUP] 1 2 [/SUP], Takashi Ishio[SUP] 1 [/SUP], Emi Yokoyama[SUP] 1 [/SUP], Koh Izumiyama[SUP] 1 [/SUP], Makoto Saito[SUP] 1 [/SUP], Haruna Muraki[SUP] 3 4 [/SUP], Masanobu Morioka[SUP] 1 [/SUP], Takanori Teshima[SUP] 2 [/SUP], Takeshi Kondo[SUP] 1 [/SUP]
Affiliations
Abstract
Data for COVID-19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 patients with ITP, anti-severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate for ITP patients was 91.3%, comparable to that in healthy controls (HCs). However, the antibody titre in ITP patients was significantly lower than that in HCs and declined with ageing. Furthermore, the antibody titre in ITP patients who received a minimum prednisolone dose of at least 5 mg/day at any time-point at or after initial vaccination was lower than that in other patients.
Keywords: COVID-19; SARS-CoV-2; corticosteroids; humoral response; immune thrombocytopenia (ITP); vaccine.
. 2022 Nov 28.
doi: 10.1111/bjh.18578. Online ahead of print.
Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia
Akio Mori[SUP] 1 [/SUP], Masahiro Onozawa[SUP] 2 [/SUP], Mirei Kobayashi[SUP] 1 [/SUP], Shihori Tsukamoto[SUP] 1 [/SUP], Hajime Senjo[SUP] 1 2 [/SUP], Takashi Ishio[SUP] 1 [/SUP], Emi Yokoyama[SUP] 1 [/SUP], Koh Izumiyama[SUP] 1 [/SUP], Makoto Saito[SUP] 1 [/SUP], Haruna Muraki[SUP] 3 4 [/SUP], Masanobu Morioka[SUP] 1 [/SUP], Takanori Teshima[SUP] 2 [/SUP], Takeshi Kondo[SUP] 1 [/SUP]
Affiliations
- PMID: 36442510
- DOI: 10.1111/bjh.18578
Abstract
Data for COVID-19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 patients with ITP, anti-severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate for ITP patients was 91.3%, comparable to that in healthy controls (HCs). However, the antibody titre in ITP patients was significantly lower than that in HCs and declined with ageing. Furthermore, the antibody titre in ITP patients who received a minimum prednisolone dose of at least 5 mg/day at any time-point at or after initial vaccination was lower than that in other patients.
Keywords: COVID-19; SARS-CoV-2; corticosteroids; humoral response; immune thrombocytopenia (ITP); vaccine.